Vaxxas

Why Vaxxas exists

Brisbane-based Vaxxas is commercialising its proprietary high-density microarray patch (HD-MAP), a needle-free platform designed to improve vaccine performance and simplify logistics. Research cited in the article shows influenza vaccines delivered via HD-MAP remain stable for up to 12 months at 40 °C, significantly reducing cold-chain requirements. The company is currently running its largest Phase 1 study to date in the United States with more than 250 participants, pairing HD-MAP with a pre-pandemic influenza vaccine under BARDA backing. In Europe, Vaxxas leads a consortium with SK Bioscience and IDT Biologika to develop next-generation seasonal and pandemic flu vaccines. The EU initiative could ultimately provide up to A$250 million to carry successful candidates through late-stage trials and registration. Near-term, an initial €12.9 million tranche will fund a Phase 1 clinical trial and preclinical work on HD-MAP delivered flu vaccines. These programmes position Vaxxas to move its platform toward regulatory approval and commercial deployment, while validating the technology’s potential to bolster global pandemic preparedness.